Artiva Biotherapeutics, Common Stock Price Prediction
| ARTV Stock | 10.40 0.22 2.07% |
Oversold Vs Overbought
55
Oversold | Overbought |
EPS Estimate Next Quarter (0.64) | EPS Estimate Current Year (5.08) | EPS Estimate Next Year (2.61) | Wall Street Target Price 21.25 | EPS Estimate Current Quarter (0.78) |
Using Artiva Biotherapeutics, hype-based prediction, you can estimate the value of Artiva Biotherapeutics, Common from the perspective of Artiva Biotherapeutics, response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Artiva Biotherapeutics, to buy its stock at a price that has no basis in reality. In that case, they are not buying Artiva because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Artiva Biotherapeutics, after-hype prediction price | USD 10.37 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Artiva |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Artiva Biotherapeutics,'s price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Artiva Biotherapeutics, After-Hype Price Prediction Density Analysis
As far as predicting the price of Artiva Biotherapeutics, at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Artiva Biotherapeutics, or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Artiva Biotherapeutics,, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Artiva Biotherapeutics, Estimiated After-Hype Price Volatility
In the context of predicting Artiva Biotherapeutics,'s stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Artiva Biotherapeutics,'s historical news coverage. Artiva Biotherapeutics,'s after-hype downside and upside margins for the prediction period are 3.78 and 16.96, respectively. We have considered Artiva Biotherapeutics,'s daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Artiva Biotherapeutics, is slightly risky at this time. Analysis and calculation of next after-hype price of Artiva Biotherapeutics, is based on 3 months time horizon.
Artiva Biotherapeutics, Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Artiva Biotherapeutics, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Artiva Biotherapeutics, backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Artiva Biotherapeutics,, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.02 | 6.59 | 0.03 | 0.00 | 2 Events / Month | 6 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
10.40 | 10.37 | 0.29 |
|
Artiva Biotherapeutics, Hype Timeline
Artiva Biotherapeutics, is presently traded for 10.40. The entity has historical hype elasticity of -0.03, and average elasticity to hype of competition of 0.0. Artiva is anticipated to decline in value after the next headline, with the price expected to drop to 10.37. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.29%, whereas the daily expected return is presently at 0.02%. The volatility of related hype on Artiva Biotherapeutics, is about 6783.82%, with the expected price after the next announcement by competition of 10.40. About 21.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.26. Some equities with similar Price to Book (P/B) outperform the market in the long run. Artiva Biotherapeutics, recorded a loss per share of 2.48. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be in a few days. Check out Artiva Biotherapeutics, Basic Forecasting Models to cross-verify your projections.Artiva Biotherapeutics, Related Hype Analysis
Having access to credible news sources related to Artiva Biotherapeutics,'s direct competition is more important than ever and may enhance your ability to predict Artiva Biotherapeutics,'s future price movements. Getting to know how Artiva Biotherapeutics,'s peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Artiva Biotherapeutics, may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| UL | Unilever PLC ADR | (0.16) | 7 per month | 0.00 | (0.22) | 1.08 | (1.31) | 6.60 | |
| ACU | Acme United | 0.72 | 7 per month | 0.00 | (0.06) | 3.21 | (3.00) | 9.10 | |
| ATEX | Anterix | 0.28 | 9 per month | 0.00 | (0.15) | 3.49 | (4.08) | 12.42 | |
| EWCZ | European Wax Center | 0.06 | 9 per month | 0.00 | (0.06) | 6.89 | (4.72) | 31.55 | |
| CHD | Church Dwight | 0.64 | 10 per month | 0.95 | (0.03) | 1.53 | (1.74) | 6.62 | |
| LECO | Lincoln Electric Holdings | (0.80) | 10 per month | 1.14 | 0.04 | 3.01 | (1.87) | 9.06 | |
| FSP | Franklin Street Properties | (0.06) | 9 per month | 2.42 | 0.09 | 5.00 | (4.22) | 14.81 |
Artiva Biotherapeutics, Additional Predictive Modules
Most predictive techniques to examine Artiva price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Artiva using various technical indicators. When you analyze Artiva charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Artiva Biotherapeutics, Predictive Indicators
The successful prediction of Artiva Biotherapeutics, stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Artiva Biotherapeutics, Common, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Artiva Biotherapeutics, based on analysis of Artiva Biotherapeutics, hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Artiva Biotherapeutics,'s market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Artiva Biotherapeutics,'s related companies. | 2021 | 2022 | 2023 | 2024 (projected) | ROE | 0.81 | 0.41 | 0.17 | 0.16 | Income Quality | 0.21 | 0.86 | 1.65 | 1.73 |
Story Coverage note for Artiva Biotherapeutics,
The number of cover stories for Artiva Biotherapeutics, depends on current market conditions and Artiva Biotherapeutics,'s risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Artiva Biotherapeutics, is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Artiva Biotherapeutics,'s long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Artiva Biotherapeutics, Short Properties
Artiva Biotherapeutics,'s future price predictability will typically decrease when Artiva Biotherapeutics,'s long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Artiva Biotherapeutics, Common often depends not only on the future outlook of the potential Artiva Biotherapeutics,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Artiva Biotherapeutics,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 9.4 M | |
| Cash And Short Term Investments | 77 M |
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.